Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy
Background. It is known that many patients with osteosarcoma have high serum alkaline phosphatase (SAP) levels. The prognostic significance of this finding, however, is still controversial. Methods. The pretreatment SAP levels of 656 patients with osteosarcoma of the extremities (107 metastatic and...
Gespeichert in:
| Veröffentlicht in: | Cancer 1993-02, Vol.71 (4), p.1224-1230 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1230 |
|---|---|
| container_issue | 4 |
| container_start_page | 1224 |
| container_title | Cancer |
| container_volume | 71 |
| creator | Bacci, Gaetano Picci, Piero Ferrari, Stefano Orlandi, Maurizio Ruggieri, Pietro Casadei, Roberto Ferraro, Andrea Biagini, Roberto Battistini, Alberto |
| description | Background. It is known that many patients with osteosarcoma have high serum alkaline phosphatase (SAP) levels. The prognostic significance of this finding, however, is still controversial.
Methods. The pretreatment SAP levels of 656 patients with osteosarcoma of the extremities (107 metastatic and 549 localized at presentation) were examined to evaluate whether the enzyme levels had a clinical value in predicting the course of the disease.
Results. The percentage of patients with increased SAP levels was significantly higher in the metastatic group than in the group of patients with localized disease (91.5% versus 61.3%; P > 0.001). In the latter group, treated with adjuvant and neoadjuvant chemotherapy, the relapse rate was significantly higher in patients with elevated pretreatment SAP levels than in those with normal levels (55.1% versus 26.4%; P > 0.001). Among patients with elevated SAP levels, the percentage of relapses was higher in patients with high levels of the enzyme in comparison with patients with moderately elevated values (66.4% versus 47%; P > 0.05). After treatment, SAP levels almost always return to normal values, and a correlation between postoperative levels of the enzyme and prognosis could not be made.
Conclusions. These data demonstrate that in osteosarcoma of the extremities, pretreatment SAP levels have a prognostic value and they should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials. |
| doi_str_mv | 10.1002/1097-0142(19930215)71:4<1224::AID-CNCR2820710409>3.0.CO;2-M |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75585117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75585117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4989-2b5b90e2e1ce3077c7dc6ce7861531d39005942de08639b5846d5c1ab135f5683</originalsourceid><addsrcrecordid>eNqVkV-L1DAUxYso67j6EYQ8iLgPHfO3aUYRlvpvYdcRURB8CGl6u81u23ST1mW-hp_YjjMO6IPgU-7lnBwO95ckBcFLgjF9TrCSKSacPiNKMUyJOJFkxV8SSvlqdXr2Oi0-FJ9oTrEkmGP1ii3xsli_oOnFnWRx-H03WWCM81Rw9vV-8iDGq3mVVLCj5CjnTEglF8mPj8Ff9j6OzqLoLntXO2t6C8jXKEKYOmTaa9O6HtDQ-Dg0ZjQRUAcmTgE66MeIXI8GM7pf860bGzTHgY8mWN8ZNAYwI1Q7xVRX03fTj8gH1IM_rLaBzo8NBDNsHib3atNGeLR_j5Mvb998Lt6n5-t3Z8XpeWq5ylVKS1EqDBSIBYaltLKymQWZZ0QwUjGFsVCcVoDzjKlS5DyrhCWmJEzUIsvZcfJ0lzsEfzNBHHXnooW2NXOzKWopRC4IkbPx285og48xQK2H4DoTNppgvSWmtzfX25vr38S0JJrrLTGtZ2L6T2KaaayLtab6Yk5_vK8xlR1Uh-w9oll_stdNtKatw4zHxYONZ1TNobOt3tluXQub_2v4z4J_KewnWRXECg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75585117</pqid></control><display><type>article</type><title>Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bacci, Gaetano ; Picci, Piero ; Ferrari, Stefano ; Orlandi, Maurizio ; Ruggieri, Pietro ; Casadei, Roberto ; Ferraro, Andrea ; Biagini, Roberto ; Battistini, Alberto</creator><creatorcontrib>Bacci, Gaetano ; Picci, Piero ; Ferrari, Stefano ; Orlandi, Maurizio ; Ruggieri, Pietro ; Casadei, Roberto ; Ferraro, Andrea ; Biagini, Roberto ; Battistini, Alberto</creatorcontrib><description>Background. It is known that many patients with osteosarcoma have high serum alkaline phosphatase (SAP) levels. The prognostic significance of this finding, however, is still controversial.
Methods. The pretreatment SAP levels of 656 patients with osteosarcoma of the extremities (107 metastatic and 549 localized at presentation) were examined to evaluate whether the enzyme levels had a clinical value in predicting the course of the disease.
Results. The percentage of patients with increased SAP levels was significantly higher in the metastatic group than in the group of patients with localized disease (91.5% versus 61.3%; P > 0.001). In the latter group, treated with adjuvant and neoadjuvant chemotherapy, the relapse rate was significantly higher in patients with elevated pretreatment SAP levels than in those with normal levels (55.1% versus 26.4%; P > 0.001). Among patients with elevated SAP levels, the percentage of relapses was higher in patients with high levels of the enzyme in comparison with patients with moderately elevated values (66.4% versus 47%; P > 0.05). After treatment, SAP levels almost always return to normal values, and a correlation between postoperative levels of the enzyme and prognosis could not be made.
Conclusions. These data demonstrate that in osteosarcoma of the extremities, pretreatment SAP levels have a prognostic value and they should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19930215)71:4<1224::AID-CNCR2820710409>3.0.CO;2-M</identifier><identifier>PMID: 8435797</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>adjuvant chemotherapy ; Adult ; Age Factors ; alkaline phosphatase ; Alkaline Phosphatase - blood ; Amputation ; Biological and medical sciences ; Bone Neoplasms - drug therapy ; Bone Neoplasms - enzymology ; Bone Neoplasms - secondary ; Bone Neoplasms - surgery ; Chemotherapy, Adjuvant ; Diseases of the osteoarticular system ; Extremities - surgery ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms - enzymology ; Lung Neoplasms - secondary ; Lung Neoplasms - surgery ; Male ; Medical sciences ; Middle Aged ; neoadjuvant chemotherapy ; Neoplasm Recurrence, Local ; Neoplasm Staging ; osteosarcoma ; Osteosarcoma - drug therapy ; Osteosarcoma - enzymology ; Osteosarcoma - secondary ; Osteosarcoma - surgery ; Prognosis ; Salvage Therapy ; Survival Rate ; Tumors of striated muscle and skeleton</subject><ispartof>Cancer, 1993-02, Vol.71 (4), p.1224-1230</ispartof><rights>Copyright © 1993 American Cancer Society</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4989-2b5b90e2e1ce3077c7dc6ce7861531d39005942de08639b5846d5c1ab135f5683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4629710$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8435797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bacci, Gaetano</creatorcontrib><creatorcontrib>Picci, Piero</creatorcontrib><creatorcontrib>Ferrari, Stefano</creatorcontrib><creatorcontrib>Orlandi, Maurizio</creatorcontrib><creatorcontrib>Ruggieri, Pietro</creatorcontrib><creatorcontrib>Casadei, Roberto</creatorcontrib><creatorcontrib>Ferraro, Andrea</creatorcontrib><creatorcontrib>Biagini, Roberto</creatorcontrib><creatorcontrib>Battistini, Alberto</creatorcontrib><title>Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background. It is known that many patients with osteosarcoma have high serum alkaline phosphatase (SAP) levels. The prognostic significance of this finding, however, is still controversial.
Methods. The pretreatment SAP levels of 656 patients with osteosarcoma of the extremities (107 metastatic and 549 localized at presentation) were examined to evaluate whether the enzyme levels had a clinical value in predicting the course of the disease.
Results. The percentage of patients with increased SAP levels was significantly higher in the metastatic group than in the group of patients with localized disease (91.5% versus 61.3%; P > 0.001). In the latter group, treated with adjuvant and neoadjuvant chemotherapy, the relapse rate was significantly higher in patients with elevated pretreatment SAP levels than in those with normal levels (55.1% versus 26.4%; P > 0.001). Among patients with elevated SAP levels, the percentage of relapses was higher in patients with high levels of the enzyme in comparison with patients with moderately elevated values (66.4% versus 47%; P > 0.05). After treatment, SAP levels almost always return to normal values, and a correlation between postoperative levels of the enzyme and prognosis could not be made.
Conclusions. These data demonstrate that in osteosarcoma of the extremities, pretreatment SAP levels have a prognostic value and they should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials.</description><subject>adjuvant chemotherapy</subject><subject>Adult</subject><subject>Age Factors</subject><subject>alkaline phosphatase</subject><subject>Alkaline Phosphatase - blood</subject><subject>Amputation</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - enzymology</subject><subject>Bone Neoplasms - secondary</subject><subject>Bone Neoplasms - surgery</subject><subject>Chemotherapy, Adjuvant</subject><subject>Diseases of the osteoarticular system</subject><subject>Extremities - surgery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lung Neoplasms - enzymology</subject><subject>Lung Neoplasms - secondary</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>neoadjuvant chemotherapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>osteosarcoma</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - enzymology</subject><subject>Osteosarcoma - secondary</subject><subject>Osteosarcoma - surgery</subject><subject>Prognosis</subject><subject>Salvage Therapy</subject><subject>Survival Rate</subject><subject>Tumors of striated muscle and skeleton</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkV-L1DAUxYso67j6EYQ8iLgPHfO3aUYRlvpvYdcRURB8CGl6u81u23ST1mW-hp_YjjMO6IPgU-7lnBwO95ckBcFLgjF9TrCSKSacPiNKMUyJOJFkxV8SSvlqdXr2Oi0-FJ9oTrEkmGP1ii3xsli_oOnFnWRx-H03WWCM81Rw9vV-8iDGq3mVVLCj5CjnTEglF8mPj8Ff9j6OzqLoLntXO2t6C8jXKEKYOmTaa9O6HtDQ-Dg0ZjQRUAcmTgE66MeIXI8GM7pf860bGzTHgY8mWN8ZNAYwI1Q7xVRX03fTj8gH1IM_rLaBzo8NBDNsHib3atNGeLR_j5Mvb998Lt6n5-t3Z8XpeWq5ylVKS1EqDBSIBYaltLKymQWZZ0QwUjGFsVCcVoDzjKlS5DyrhCWmJEzUIsvZcfJ0lzsEfzNBHHXnooW2NXOzKWopRC4IkbPx285og48xQK2H4DoTNppgvSWmtzfX25vr38S0JJrrLTGtZ2L6T2KaaayLtab6Yk5_vK8xlR1Uh-w9oll_stdNtKatw4zHxYONZ1TNobOt3tluXQub_2v4z4J_KewnWRXECg</recordid><startdate>19930215</startdate><enddate>19930215</enddate><creator>Bacci, Gaetano</creator><creator>Picci, Piero</creator><creator>Ferrari, Stefano</creator><creator>Orlandi, Maurizio</creator><creator>Ruggieri, Pietro</creator><creator>Casadei, Roberto</creator><creator>Ferraro, Andrea</creator><creator>Biagini, Roberto</creator><creator>Battistini, Alberto</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930215</creationdate><title>Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy</title><author>Bacci, Gaetano ; Picci, Piero ; Ferrari, Stefano ; Orlandi, Maurizio ; Ruggieri, Pietro ; Casadei, Roberto ; Ferraro, Andrea ; Biagini, Roberto ; Battistini, Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4989-2b5b90e2e1ce3077c7dc6ce7861531d39005942de08639b5846d5c1ab135f5683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>adjuvant chemotherapy</topic><topic>Adult</topic><topic>Age Factors</topic><topic>alkaline phosphatase</topic><topic>Alkaline Phosphatase - blood</topic><topic>Amputation</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - enzymology</topic><topic>Bone Neoplasms - secondary</topic><topic>Bone Neoplasms - surgery</topic><topic>Chemotherapy, Adjuvant</topic><topic>Diseases of the osteoarticular system</topic><topic>Extremities - surgery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lung Neoplasms - enzymology</topic><topic>Lung Neoplasms - secondary</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>neoadjuvant chemotherapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>osteosarcoma</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - enzymology</topic><topic>Osteosarcoma - secondary</topic><topic>Osteosarcoma - surgery</topic><topic>Prognosis</topic><topic>Salvage Therapy</topic><topic>Survival Rate</topic><topic>Tumors of striated muscle and skeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bacci, Gaetano</creatorcontrib><creatorcontrib>Picci, Piero</creatorcontrib><creatorcontrib>Ferrari, Stefano</creatorcontrib><creatorcontrib>Orlandi, Maurizio</creatorcontrib><creatorcontrib>Ruggieri, Pietro</creatorcontrib><creatorcontrib>Casadei, Roberto</creatorcontrib><creatorcontrib>Ferraro, Andrea</creatorcontrib><creatorcontrib>Biagini, Roberto</creatorcontrib><creatorcontrib>Battistini, Alberto</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bacci, Gaetano</au><au>Picci, Piero</au><au>Ferrari, Stefano</au><au>Orlandi, Maurizio</au><au>Ruggieri, Pietro</au><au>Casadei, Roberto</au><au>Ferraro, Andrea</au><au>Biagini, Roberto</au><au>Battistini, Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1993-02-15</date><risdate>1993</risdate><volume>71</volume><issue>4</issue><spage>1224</spage><epage>1230</epage><pages>1224-1230</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Background. It is known that many patients with osteosarcoma have high serum alkaline phosphatase (SAP) levels. The prognostic significance of this finding, however, is still controversial.
Methods. The pretreatment SAP levels of 656 patients with osteosarcoma of the extremities (107 metastatic and 549 localized at presentation) were examined to evaluate whether the enzyme levels had a clinical value in predicting the course of the disease.
Results. The percentage of patients with increased SAP levels was significantly higher in the metastatic group than in the group of patients with localized disease (91.5% versus 61.3%; P > 0.001). In the latter group, treated with adjuvant and neoadjuvant chemotherapy, the relapse rate was significantly higher in patients with elevated pretreatment SAP levels than in those with normal levels (55.1% versus 26.4%; P > 0.001). Among patients with elevated SAP levels, the percentage of relapses was higher in patients with high levels of the enzyme in comparison with patients with moderately elevated values (66.4% versus 47%; P > 0.05). After treatment, SAP levels almost always return to normal values, and a correlation between postoperative levels of the enzyme and prognosis could not be made.
Conclusions. These data demonstrate that in osteosarcoma of the extremities, pretreatment SAP levels have a prognostic value and they should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8435797</pmid><doi>10.1002/1097-0142(19930215)71:4<1224::AID-CNCR2820710409>3.0.CO;2-M</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1993-02, Vol.71 (4), p.1224-1230 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75585117 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | adjuvant chemotherapy Adult Age Factors alkaline phosphatase Alkaline Phosphatase - blood Amputation Biological and medical sciences Bone Neoplasms - drug therapy Bone Neoplasms - enzymology Bone Neoplasms - secondary Bone Neoplasms - surgery Chemotherapy, Adjuvant Diseases of the osteoarticular system Extremities - surgery Female Follow-Up Studies Humans Lung Neoplasms - enzymology Lung Neoplasms - secondary Lung Neoplasms - surgery Male Medical sciences Middle Aged neoadjuvant chemotherapy Neoplasm Recurrence, Local Neoplasm Staging osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - enzymology Osteosarcoma - secondary Osteosarcoma - surgery Prognosis Salvage Therapy Survival Rate Tumors of striated muscle and skeleton |
| title | Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T18%3A11%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20serum%20alkaline%20phosphatase%20measurements%20in%20patients%20with%20osteosarcoma%20treated%20with%20adjuvant%20or%20neoadjuvant%20chemotherapy&rft.jtitle=Cancer&rft.au=Bacci,%20Gaetano&rft.date=1993-02-15&rft.volume=71&rft.issue=4&rft.spage=1224&rft.epage=1230&rft.pages=1224-1230&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19930215)71:4%3C1224::AID-CNCR2820710409%3E3.0.CO;2-M&rft_dat=%3Cproquest_cross%3E75585117%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75585117&rft_id=info:pmid/8435797&rfr_iscdi=true |